Seal Biosciences Seal Biosciences Seal Biosciences Seal Biosciences Seal Biosciences

About Us

Seal Biosciences Inc. is focused on the development and commercialization of a new prognostic biomarker to identify cancer patients who would benefit most from anti-Epidermal Growth Factor Receptor (anti-EGFR) therapy, initially in metastatic colorectal cancer (mCRC).

Our Team

Management Team

Dr. Raitt has over 15 years experience in the Biotech industry; Group Leader Oncology/Immunology Target ID & Validation in early drug discovery; Associate Director, Pipeline Sourcing, Nycomed Founder & Principal, Bay Biotech Consulting.

Patrik has been working for the last +15 years as a CFO and finance advisor for a number of public and privately held companies (VC & PE backed). He has over 20 years of experience in senior leadership roles in Global and International companies. Mr. Jeanmonod has been instrumental in Company M&A, fund raising (equity and debt). Mr. Jeanmonod holds a Master’s Degree in Finance from the University of Geneva.

Valerie is a corporate and securities attorney with over 17 years of experience working with founders and technology companies from formation through IPO, with a focus on venture capital financings, public offerings, debt transactions, mergers and acquisitions, corporate governance and SEC, NASDAQ and Sarbanes-Oxley compliance. Her experience includes practicing law at Wilson Sonsini Goodrich & Rosati in Palo Alto, California and serving as in-house counsel to biotechnology companies in the Bay Area. She also provides consulting legal services to multiple technology start-ups. Valerie received her B.A. in Political Science from the University of California, Irvine and her J.D. from Cornell Law School.

Medical Team

Leading authority in the Ras signaling field, Dr. Roose is currently an Associate Professor with tenure at UCSF and runs a research team of 12 people with a focus on understanding the aberrant biochemical signals that drive diseases like leukemia, colorectal cancer, and autoimmunity.

15+ years as Chief of Surgical Oncology at UCSF; Principal Investigator of two international clinical studies of biomarkers involving >3000 patients with colon cancer.

Dr. P. Depeille, currently scientist, is working in Dr. Jeroen Roose at UCSF. He has worked in cancer field for 15 years focusing on different aspect for understanding cancer resistance and cellular mechanism. His work led to the discovery of the novel pathway mediating a critical tumor suppressor function on the Ras pathway in colorectal cancer.